Sutro Biopharma Dosed the First Patient in the Dose-Expansion Cohort of the Phase 1 STRO-002 Study

Sutro Biopharma Therapeutic Discovery and Technology
Sutro Biopharma (STRO) uses precise protein engineering and rational design for therapeutic discovery. The firm’s proprietary integrated cell-free protein synthesis platform known as XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of the following: